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Highlights 
 We introduce a novel approach to the analysis of life science innovation 
 With a triangular theoretical framework inclusive of all innovation actors 
 We have developed foresighting tools that analyse these interactions 
Abstract   
This paper presents an approach developed by the Innogen Centre for the analysis of 
systems of innovation. The approach, developed through the study of innovation in 
the life sciences, is unique in that it features a triangular view, alongside 
consideration of the behaviours and interactions between innovators, regulators and 
policymakers, and advocacy and public interest groups. Furthermore, while the 
approach can be characterised as co-evolutionary and system-based, it also allows 
for the user to shift from the macro to micro – considering the impact of institutions 
on actors and innovation within an institutional milieu, but also considering the 
individual behaviours and business plans or actions of the actors involved. This 
paper presents both the approach itself and how the approach was developed. 
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1  Introduction 
This paper describes the development and use of a new methodological tool and 
analytical approach to the study of the life sciences that is rooted in 
interdisciplinarity. This, we argue, is needed to capture the complexity and 
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interconnectedness of the sector’s knowledge production and product development 
processes that constitute the life science innovation system. Our focus on life science 
sectors where regulatory and public interests play a key role builds on recent 
complementary work (Crespi and Quatraro, 2013; Kerr et al., 2013). The approach 
presented here is unique in that it features a triangular view, and equitable 
consideration, of the behaviours and interactions between innovators, regulators and 
policymakers, and advocacy and interest groups. Furthermore, while a co-
evolutionary system-based view, the approach also allows for the user to shift from 
the macro to micro – considering the impact of institutions on actors and innovation 
within an institutional milieu, but also considering the individual behaviours and 
business plans or actions of the actors involved. 
Understanding of innovation in the life sciences depends on pulling together three 
dimensions: first, a sense of the intradisciplinary and interdisciplinary complexity of 
the different disciplines that generate knowledge in the life sciences; second, an 
understanding of the wide range of science-industrial sectors that translate this 
knowledge into new products and processes; and thirdly, the social science 
disciplines needed to understand the social relations of these activities, and to build 
an integrated overview and effective decision- and policy-making for life sciences. 
By integrating these three dimensions, and treating the opportunities and challenges 
of life science innovation as inherently systemic in nature, we developed a novel set 
of methodological and conceptual tools. These tools better capture and understand 
the significant changes in the life sciences that are emerging from interactions 
between three key sets of actors: 
 The innovators, the broad group of actors involved in the production of 
science, technology and product innovations. They may be located in public 
or private sector research settings, small and large companies, and within 
new networks and partnerships. 
 Policy makers and regulators ranging from narrowly organised regulatory 
bodies for sub-parts of the innovation system, to those responsible for 
bridging boundaries and proposing new policy and regulatory innovations to 
ensure appropriate governance of the sector. 
 Citizens and other users (such as patient interest groups and advocacy 
organisations) that provide an important public ‘check’, but also informed 
pressure on the other two sets of stakeholders, concerning for example 
improved food quality and new drugs for rare diseases. 
It is the ability to look at the interaction between these three sets of actors, in breadth 
and depth, and without bias, that provides the value added to Innogen’s approach. 
We introduce a selection of the tools we have built, which provide a means of 
conceptualising and analysing the interactions among the actors with the aim of 
identifying gaps, weaknesses and opportunities to improve scientific and 
technological foresighting. We argue that foresight will be more accurate, and 
therefore have far greater and positive impact on policy, innovation and society, if it 
is based on a formal integrative approach such as the one we present. The methods 
section (section 2) describes the evolution of our approach from the late 1980s to 
date. In section 3 we provide the theoretical underpinnings of the approach. Section 
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4 shows how we apply the approach to the analysis of innovation in the life sciences, 
and in section 5 we give a sense of how the approach works in detail with the case of 
regenerative medicine. We present our conclusions in section 6.  
2  Method 
Our initial framework was developed over more than a decade from the late 1980s. 
As early as 1990, Tait suggested that misgivings would grow about the safety of new 
technologies in agriculture, especially those based on genetic modification (GM). She 
suggested that the outcome of these concerns would depend on complex interactions 
between industrial innovation, government policy, risk regulation and public 
attitudes: ‘In the resulting system, perturbations in any one factor will have a major 
impact on the others, through a set of feedback loops (Tait, 1990, p 1).’ 
Tait’s concern, as expressed in evidence she gave for the UK Economic and Social 
Research Council (ESRC) to a UK parliamentary committee, was that industrial 
lobbying would destabilise existing risk regulation: 
‘[Industrial] lobbying activity …  is also likely to diminish industry’s perceived 
trustworthiness, and hence reinforce adverse public attitudes. The latter would then 
feed back, directly and through pressure to increase the level of risk regulation, to 
cut back on industry investment (1992, p 192)’.  
She went on to describe the results of a public attitude survey she had conducted 
concerning new biotechnologies, particularly genetic modification of plants and 
micro-organisms:  
‘The overall levels of concern expressed, among all groups, were high. This leads us 
to the tentative conclusion, a worrying one from industry’s perspective, that these 
negative attitudes may be triggered into overt expression in behaviour by some 
relatively minor event’. 
Tait, then, picked up these concerns, and the need for systemic integrated analysis, 
well before GM became a public issue and before GM products went onto the 
market. At the time her suggestion that concerns might arise was not taken 
seriously. Policy makers and regulators did not sense the growing public concerns 
about new agricultural technologies. Within a few years, however, the GM ‘debate’ 
had exploded and was to fundamentally change the nature of European approaches 
to food production. We decided to focus on analysing these issues. A range of 
research projects from the mid-1990s to the early 2000s focused on agricultural 
processes and practices (Chataway et al., 2004; Chataway et al., 2006). 
This research was consolidated by the establishment of the UK Innogen research 
centre (the ESRC Centre for Social and Economic Research on Innovation in 
Genomics - Innogen) in 2002 to study the new science and technologies emerging in 
the life science industries – human health, crop and animal. Our approach used and 
further developed the tools we had applied in the previous decade (Tait, 2007; 
Wield, 2008). We based the tools on a triangular framework based on the view that 
the major changes, and potential surprises that could destabilise innovation policy, 
would come from crucial systemic interactions between the three main sets of actors. 
Our research has shown that the interactions and collaborations of the three sets of 
actors with each other, and not simply their individual characteristics and actions, 
are important. 
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For example, our research with drug regulators and producers suggested that the 
weakening of drug industry innovation models could be reappraised as a mismatch 
between: the nature of new life science innovations, the nature of the companies that 
could best exploit these innovations, public and private expectation of new drugs 
and treatments, and regulatory systems that were designed around twentieth 
century models of drug development (Tait, Chataway and Wield,  2008a, Tait et al , 
2008b, Wield et al 2013). Such a research approach involves: knowledge generation 
from multiple sources in a more ‘open’ way including from users of knowledge, 
such as patients with rare diseases and their organisations; the sharing and 
combination of ideas in an interdisciplinary way; and the contextualisation of these 
triadic interactions in particular situations – each with different and evolving 
routines. 
The evolution of our approach has allowed development of a framework and 
empirical tools. In this paper we introduce one of these, the Strategic Analysis of 
Advanced Technology Innovation Systems (STRATIS) approach. The methodology 
provides an overarching framework that acts as a basis for interdisciplinary 
integration across academic disciplines, actor perspectives and across a wide range 
of areas of application. 
 3   Theoretical underpinnings 
Our early research on the life sciences made it clear that simple analysis of the 
relationship between science and industry did not pick up the reasons why 
innovation was taking place in the life science sectors. Similarly, a focus on public 
attitudes alone, or only on regulators, did not allow rigorous analysis of the 
changing regulatory environment. A focus on both ‘policy’ and ‘public’ interests was 
necessary (Burawoy, 2005, Mastroeni et al., 2012). In order to pull together analysis 
of the various scientific disciplines and the complex social interactions, our approach 
to theory building began by working from in-depth analysis of our empirical data on 
complex situations. It was informed by four theoretical underpinnings: (1) specificity 
of the life sciences, emphasising the complex role of multi interest stakeholders; (2) 
how this specificity influences the sectoral nature of the life sciences; (3) its co-
evolutionary approaches; and (4) its systemic characteristics. 
3.1  Specificity of the life sciences 
Our theoretical approach acknowledges and classifies the multi-stakeholder nature 
of the life science sector in order to capture its specificity and its strongly value-
oriented environment. 
The stakeholders include important non-market actors (such as universities, public 
sector research institutes, as well as patients, consumers, and health services). Even 
the nature of science is different.  For example, Dupre (1995) argues that biological 
knowledge differs in its complexity and scientific disunity from sciences such as 
physics and chemistry. It does not appear to have the methodological unity or 
underlying theory to link its disparate fields. Such analyses may lead to a new unity 
of knowledge that is more complex and involves a wider range of actors (Wield et al, 
2013). If we take the science and innovation together with the complex governance 
systems and public and non-market actors, we have a sector with complex 
knowledge interactions. 
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We add out triadic approach to a systems perspective to deal with complexity. 
Historically, the first category, ‘innovator’, has been treated as a firm-based activity 
with markets as the main testing ground for innovation success or failure. However, 
in the life sciences, innovation happens in a wide range of social and economic 
activities, many beyond that of the single firm. Life science innovation increasingly 
involves ‘a wide range of external actors and sources to help them achieve and 
sustain innovation’ (Laursen and Slater, 2006, p131). Although pharmaceutical 
companies are still the dominant actors in health, and agro-chemical and seed 
companies in agro systems, innovation in the life sciences includes a relatively 
higher degree of non-firm and non-market actors and interactions. Scientific labs in 
universities and large public research institutes are major actors, as are public health 
systems. There are a range of complex institutional arrangements such as public-
private partnerships for rare and neglected diseases and patient-induced research 
networks. Our research on innovation dynamics suggests there is a broadening 
conceptualisation of innovation strategies.  
Innovation now requires knowledge from multiple sources, in a more ‘open’ way, 
including from users. OECD evidences an ‘explosion in the development of 
knowledge networks and markets’ and suggests this has led to increased enabling of 
open innovation (OECD, 2012, p 11). It requires different sources of knowledge co-
evolving during the innovation process, each context being different and specific, 
with its own routines and traditions. It is clear, for example, that big pharma 
requires a wide range of science, clinical trial, and other outsourced producers. 
(Wield et al, 2013; Wield, 2013; Rafols et al., 2014; Mittra, 2016). On occasion, 
openness allows significant power to be devolved to multiple actors, even though 
the stronger (usually big pharma) partner can capture more value from 
collaborations (Gambardella and Panico, 2014). The category of innovator is 
complex, containing firm-based, private, market oriented actors, but also public, 
non-firm, non-market actors.  
The second category is centred on public actors, such as regulators, though these 
operate largely within market based environments. Although regulation is an 
important part of the activity in many industries and sectors, it is a more important 
part of the life science industries. Our theoretical underpinnings give regulation a 
key role, perhaps not controlling but certainly central to explaining the dominance of 
the conventional drug discovery innovation model. We have shown that the 
dominance of the large pharmaceutical firms is, in large part, explained by their 
ability to invest the huge amounts needed to take drugs through the clinical trials 
process (Tait, 2007; Mittra, 2016). Start-up biotech firms cannot do this, as they do 
not have the resources and the venture investment model prefers shorter-term pay-
offs from selling at earlier stages in the clinical trials process. 
Regulatory systems can, by a set of incremental changes over time, get out of step 
with the regulated area, and also become extremely complicated so that further 
change has unexpected implications (Tait et al.,  2007; Chataway et al., 2006). As a 
regulatory regime becomes more complex, its practices are likely to become more 
fragmented. Regulators operate within a network of actors with competing interests, 
values and power. Regulation can therefore be analysed in a similar way to more 
open innovation processes, and thus on the interactions between the triad of actors.  
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The final category, citizens and public stakeholder groups, contains a rich 
combination of interests and values. The anti-GM advocacy groups and anti-animal 
experimentation groups are strongly against some new biotechnologies, for example, 
whilst rare-disease patient-interest groups are more closely allied to those innovators 
and regulators that are working towards new therapies (Wield et al 2013). We, like 
Burawoy (2005), clearly separate professional ‘policy’ from ‘public’ approaches. 
We have analysed this latter category in two ways. First, through an interests/values 
type approach (Tait, 2001). Values play a key role in most fields of the life sciences, 
from GM food, cloned animals, to various new health therapies, and issues around 
ownership of intellectual property (IP), bringing strong opinions that cannot be 
changed by negotiation. Interests on the other hand, allow for a more nuanced and 
pragmatic approach to decision-making. An example of the latter is the efforts to 
negotiate ‘benefit sharing’ for communities affected by IP arising from local 
medicinal plants.  
Second, we use the concept co-production, where citizen’s groups can often be co-
producers of knowledge concerning new therapies. Epstein’s work (1996, 2007) 
illustrates the importance of public ‘patient’ knowledge in the development of new 
therapies. His first work, concerning the development of AIDS therapies to AIDS 
associated retrovirus (ARV) therapies (1996) described the levels and layers of 
knowledge of non-scientists AIDS activists, and how they gained a voice in the 
scientific world. ‘The vigorous participation of self-educated activists – and more 
broadly, the rise of knowledge-empowered communities that monitor the course of 
the medical research – has had momentous effects on the development of AIDS 
treatments. These treatments have transformed the procedures by which drugs are 
tested, in which test results are interpreted, and the processes by which those 
interpretations are then used in the licensing of drugs for sale’ (Epstein, 1996, p33).  
A further breakthrough was the role of clinical trials and the pressure from activists 
to ‘bring the patients back in’ (Epstein, 1996, p40) which led to fast track legislation 
and rare disease and orphan drug legislation. Epstein (2007) noted the growing 
inclusion of ‘more and more ordinary citizens, often organised into patient interest 
groups or broader social movements, have demanded a say in how scientists ad 
health professional groups go about their work, tossing aside the presumption that 
technical matters are best left up to the experts’ (p20-21) but also emphasises that 
‘these policy changes were not brought about by a lay social movement, pure and 
simple, but rather by a hybrid coalition linking health advocates with experts, 
bureaucrats and policymakers’ (p21).  
In addition, Haddow et al.’s research, which focused on the Scottish genetic data 
base, showed how participant involvement and knowledge could improve 
effectiveness of data collection and use (Haddow et al., 2008). Patient support groups 
have added a major dimension to the knowledge base on which new therapies are 
developed and regulated. Epstein and Haddow et al’s insights provide strong 
evidence that public advocacy can influence the production of knowledge in the life 
sciences. 
 3.2  Sectoral approaches to the life sciences 
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The specificity described above affects the sectoral nature of the life sciences, 
covering the new discoveries in biotechnology and genomics, building on a broad 
range of science disciplines – biochemical, chemistry, computer sciences, IT, 
synthetic biology and, cell biology. The knowledge generated is translated by a wide 
range of industrial actors and subsectors into new products and processes. The life 
sciences as a sector has commonalities but also important differences: agro-
biotechnology including GM crops, pharma and biopharma, industrial 
biotechnology, devices and new therapies. Malerba advanced the concept of sectoral 
innovation systems as a way of building a coherent analysis of sectors of economic 
activity, previously not well studied either methodologically or theoretically (2002).  
Malerba proposed that a sectoral system of innovation and production is ‘a set of 
new and established products for specific uses and the set of agents carrying out 
market and non-market interactions for the creation, production and sale of those 
products … . Sectoral systems have a knowledge base, technologies, inputs and 
demand. The agents are individuals and organizations at various levels of 
aggregation, with specific learning processes, competences, organizational structure, 
beliefs, objectives and behaviours (p248)’. Malerba’s approach, therefore, captures 
the specificities that each sector faces. 
Our research, building on the work of others (Orsenigo et al., 2001; Henderson et al.,    
1999) showed that the life science sector has some key characteristics (Tait et al 2002, 
Chataway et al, 2004). For example, it has a strong science base, including university 
and public research lab knowledge. This knowledge base has been linked closely to 
firm-based R&D systems, including via big pharmaceutical companies, agrichemical 
and seed firms, and spin-out biotechnology firms. These knowledge-based inter-
organisational sectors are linked with formal intellectual property rights, including 
patents and seed rights, which are strongly defended, including in high profile legal 
actions. The life science technology regime is thus science- and IPR- based.  
Less emphasised is the ‘D’ in ‘R&D’, the technology regime elements around the 
clinical trials and agro-production trials. These trials are intimately connected with 
the regulatory systems that have grown in depth and breadth over the years: 
deepening the stages needed, and broadening out to many types of innovation 
product, trajectory and process. There is a paradox, however, since increased 
openness of the innovation process in the life sciences goes together with increasing 
constraints from regulatory complexity, which lowers the capability of small 
innovative companies and cements the power of big pharma over the life science 
value chain. We argue that it is these less emphasised parts of the sectoral system 
which have led to the increasing difficulty for new entrants to develop and succeed 
in the sector. 
Malerba (2002) mapped out four areas for future research, each of which we  
researched for the life sciences.  First,  progress in understanding of firm 
heterogeneity, structure and change within sectors, and on the role of sectoral 
institutions which we have mapped (Chataway et al, 2004; Orsenigo and Tait, 2008; 
Wield 2013). We have also built understanding of barriers to entry and the impact of 
regulatory systems on the lengthy clinical trials process which are important for 
Malerba’s second and third areas of future research: the need for taxonomies of 
sectors; and research on the relationships between elements of a sectoral system (eg 
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Mittra and Williams, 2007; Orsenigo and Tait, 2008). Malerba’s fourth area, the need 
for public policy proposals on the transformation of sectoral systems to identify 
mismatches and blockages, is exemplified by our work on policy proposals 
concerning the need for improved regulatory systems (smart regulation) and on new 
approaches to the development of public-private and more open innovation systems 
(eg Chataway et al 2006, Tait et al 2007). We have, in the process, focused hard on 
non-firm activity that can enable firm based innovative potential, showing the 
importance of open and complex knowledge management approaches (Wield 2013, 
Wield et al 2013). 
3.3   Co-evolutionary approaches  
Following directly from our finding that three broad sets of actors have shaped 
evolution, is the conclusion that these groups co-evolve in the changing life science 
sector. That is, life science industrial innovation is inter-dependent with policy and 
regulatory actors and with public actors. Mittra has described the body of 
knowledge developed over the last decade as: ‘a complex and distributed innovation 
eco-system … [that] highlights the interdependencies between different actors and 
organizations that co-produce new scientific knowledge, technologies and therapies’ 
(Mittra, 2016, p3).Geels has also suggested a triple embeddedness framework aiming 
to get beyond firms, markets and evolutionary economics (Geels, 2014; Penna and 
Geels, 2012), supporting our view that industry markets and technology co-evolve 
(our ‘innovation actors’) with civil society and broader polity. He postulates the need 
to get beyond market environments and introduces a second external environment – 
the institutional environment.  
 Geels’ industrial regime is closest to our ‘innovator category’ to which we would 
add his task environment. We, on the other hand, have characterised socio-political 
environment into two: regulation/policy; and publics. That is, we treat the 
policy/regulatory system and civil society as separate partners in the governance 
process. The specificity of the life sciences is one reason for such an approach, but 
also we think that these two categories are better analysed separately, since public 
associations and actions have very different characteristics to policy institutions. 
Thus, for Geels, with his attempt to understand better how firms get to grips with 
markets as well as environmental change and other highly disruptive changes, the 
co-evolution is between industry, markets and non-market forces. For us, with our 
attempt to understand the social forces propelling life sciences and innovation, the 
co-evolution is not so easily separated between market and non-market drivers. The 
growth of biological knowledge and its application in food and health has increased 
the importance of non-market actors, especially public actors. One major implication 
is that the management of knowledge creation and appropriability becomes ever 
more complex (Brown and Duguid, 1998) and knowledge sharing/collective 
understanding increasingly important (Cook and Brown, 1999).  
3.4  Systemic interactions 
Finally, we underpin our approach with emphasis on the systemic characteristics of 
the life science sector. Tait (2007) summarised the theoretical underpinnings of our 
systemic approach. She analysed different systemic approaches in the innovation 
literature (including complex, technological, regional, local, national and sectoral 
systems) in terms of their different perspectives on the boundary of the system. She 
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argued that the conceptual embodiment of each innovation perspective was outlined 
in the initial system description which then suggested a specific set of appropriate 
methods Tait used the sectoral systemic approach, arguing that markets and 
regulatory systems should not be seen as integral components within a dynamically 
interactive network, but rather as external to the system within the environment of 
the system ‘influencing and/or controlling it and by definition outside the control of 
the innovation system itself (2007, p. 259).  ‘Relationships between these systemic 
and environmental components determine the nature of the boundary and the ease 
with which components can cross it, either to come under the control of the system 
or to leave its control (p 261)’.  Tait felt that, although sectoral innovation systems 
thinking had described well the innovation system as a network of actors and 
relationships, focusing on the systems boundary would tighten analysis of the 
overall behaviour of the system. 
She used the drug discovery blockbuster innovation model to explain her thinking. 
Contrary to the usual thinking that new biotechnology firms would eventually bring 
a new wave of disruptive innovation, she included new biotech firms within the 
blockbuster model, not an alternative to it because biotechs were almost entirely 
within the dominant system’s control. There is little possibility at present that 
biotechnology companies will break the mould and produce a wave of creative 
destruction in the life sciences. Tait also argued that the regulatory system was 
outside the boundary and strongly influencing the nature of drug innovation. Each 
incremental change in regulation has been incorporated into the existing innovation 
system in a way that reinforces the dominant position of the multinational 
pharmaceutical companies, making it virtually impossible for any new entrant to 
break through ‘far less to develop an alternative innovation system that challenges 
that of the existing multinationals (op cit, p 262)’. So, the more open innovation 
system has not led to a broadening in the number of successful drug producers. 
Tait was able to show that specifying a system boundary suggested that some 
innovations had the potential for disruptive innovation, for example that stem cells 
could have this property in innovation, regulation and in markets but that this 
potential will depend on regulatory changes and whether new firms can break into 
the pharma dominated arena. Certainly, it seems that new business models are 
needed to accommodate new collaborative and knowledge systems 
Teece (2010) proposes that good business model design involves determining: which 
market segments should be targeted; what benefits the product/service will deliver 
to the customer; which features/technologies will be embedded within it and how 
they can best be assembled and offered; and how value will be captured and 
competitive advantage sustained. Teece argues that these issues are interrelated and 
that a business model is a conceptual rather than a financial model of a business. 
Several issues arise in applying these ideas to the development of new cell therapies. 
There is no pre-defined business model or body of experience that can be refined to 
give competitive advantage. The chosen tactics and strategies will define the 
business model rather than being defined by it – the business model has to be 
developed de novo (Mastroeni et al, 2012). The concept of dominant design is 
important here. Experimentation will be needed before a dominant design emerges 
(Tushman and Murmann, 1998).  
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The bottom line of our theoretical underpinnings is that there is no pre-determined 
business model for such disruptive innovation, creating a challenging foresight-
related task for innovators. 
4  Application to life science innovation systems 
These theoretical underpinnings allow the development of a series of evolving 
analytical approaches to the study of life science innovation. We have evidence that 
such approaches are both ambitious and also practicable. Ambitious, in the sense of 
understanding the structure and dynamics of the agro- and bio-medical industries 
and science knowledge systems, the role of regulatory and policy regimes in shaping 
innovation trajectories, and the potential for public involvement in knowledge 
creation, management and use. Practicable, in the sense of ability to navigate a 
decision-making route through the complexity of the multi-actor, complex 
institutional dynamics of the life sciences. 
The approach evolved initially through analysis of existing sectoral innovation 
systems - the agro-food sector, then the  pharmaceutical industry. Then, we analysed 
incremental changes to those sectoral systems with orphan drugs and fast track 
regulation (Milne and Tait, 2009). This work led us to reconceptualise by better 
integrating our theoretical framework based on sectoral innovation systems, 
systemic interactions, life science specificity and co-evolutionary approaches. We 
also analysed the early development of potential new therapies to address major 
needs but with no clear market.  
Our analysis of the pharmaceutical sector began with the obvious that the major 
companies depended on a blockbuster model of drug discovery innovation which 
was highly stylised around identification of promising drug targets; conducting 
multi-phase clinical trials that got increasingly complex over time, and became much 
more expensive at later stages when large numbers of humans were needed, leading 
to a small number of marketable drugs (Mittra et al., 2011; Wield, 2013). We 
described the lower productivity rate of R&D; high attrition rate of active 
compounds and rising cost of each successful drug given the large numbers of drugs 
‘lost’  during the clinical trials process (Mittra et al., 2011).  
We were able to illustrate the increasing ossification of the regulatory system which 
has led to an increasing crisis in this form of innovation, albeit within an industrial 
system that has high volumes of profit, even as profit levels decrease, allowing big 
pharma to acquire innovative smaller companies and to give funds back to 
shareholders rather than invest. One important result from our research was that the 
sclerotic regulatory system had increased the monopoly power of big pharma. New 
biotechs, for example, cannot survive the long and expensive clinical trials. Milne 
and Tait report that, of the nearly 2,000 active biotech medicines in preclinical 
development in 2009, only 15% were owned by the top 20 pharmaceutical 
companies, ‘yet big pharma owns nearly 40% of projects in late development and 
over 70% of the biotech medicines that have actually reached the market over the last 
20 years’ (2009, p 734). The long development times involve too much risk for SMEs. 
Thus, we show the increasing monopolisation of a decreasingly profitable sector. 
The blockbuster innovation model is showing symptoms of strain in terms of R&D 
efficiency, profitability and public image.  
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More open innovation models are gradually taking on the old model as a way of 
analysing changes (Wield, 2013).  The drug regulatory system is now opening up 
somewhat and becoming somewhat more flexible to accommodate more radical 
innovation. One ‘trend’ is the large increase in new therapies as a result largely of 
the FDA’s orphan drug and fast track programs. The US Orphan Drugs Act 1983 was 
a radical departure in regulatory system that proactively encouraged the 
development of new drugs for rare conditions. Since 1983, 1,700 orphan designations 
had been granted and about 300 orphan drugs approved (Milne and Tait, 2009, 
Wield, 2013). The fast track designation, begun in 1998, gives opportunity for 
priority review for development of products for serious and life threatening 
conditions, illustrating that the blockbuster innovation model can be changed by 
changing governance systems, which itself is a result of changing public 
participation and pressure from patient interest groups, with patients increasingly 
integrated into knowledge production processes. 
More recently, evidence has emerged that research into rare diseases may offer 
learning that will improve drug discovery processes more generally. Milne and Tait 
(2009) argue that the orphan drug/fast track ‘regulatory opening’ can be generalised 
both to bridge market gaps, and to provide a safe accelerated authorisation process.  
Another example is the major initiative from 2000 to build new institutional 
collaborations to bridge the gap between needs and access in developing countries. 
For example, public-private partnerships have attempted to develop ‘products and 
processes relevant to the developing world’ where ‘it is tragically obvious that the 
private sector  … cannot or will not address the needs of the sickest and the poorest’ 
(Chataway and Smith, 2006, p16).  
These experiments have brought insights to the study of the opening of, and inter-
organisational collaboratory nature of innovation, such as the importance of 
innovation integrators in more open innovation systems (OECD, 2012). ‘Innovation 
in the life sciences requires knowledge from multiple sources, in a more “open” way, 
including from users of knowledge, such as patients’ (Wield et al, 2013). This type of 
innovation involves co-evolution of different sources of knowledge interacting in a 
shared and combined way. 
5   Application to a framework of analytical tools and guidelines? 
This section shows how we have used the Innogen framework and underpinning 
theory to develop a set of foresighting tools. We have developed a framework 
(Figure 1) along with a series of guidelines that allow actors within each of our three 
categories to map the likely future outcomes of their actions as they will affect, and 
be affected by, the other two categories, the overall focus being on the success or 
otherwise of the innovation trajectory as mapped along the value chain. Conceptual 
or quantitative scenarios, or a combination of the two, can be used to incorporate 
analysis of the positions and trajectories of the relevant actors operating along the 
value chain as they interact with elements of the innovation ecosystem (Mittra et al., 
2015). The degree of the foresight challenge will depend on how early in the 
foresight process (i.e. how far from market delivery) is the innovative development 
and the degree of disruption of manufacturing processes or of markets involved. 
5.1   Strategic Analysis of Advanced Technology Innovation Systems (STRATIS)  
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The STRATIS approach, the core of the framework, allows analyses to be made from 
the perspective of scientists/innovators but also to consider the roles of 
regulators/policy makers and/or public/citizen stakeholders (Fig 1). It uses three 
levels of analysis, business models, value chains and the innovation ecosystem, and 
uses scenarios to identify key factors and interactions that may determine the 
success or failure of a novel innovative development.  
 Business model: a generic model based on in depth understanding of the range 
of business plans being developed in a specific sector or sub-sector within an 
overall value chain; it determines how firms within a sub-sector can create, 
capture and deliver economic value.  
 Value chain: the range of activities required, and of businesses involved in 
taking an innovation from conception to end use, including the linkages 
between business models needed to reach the end-market. The value chain is 
likely to include several different business models, in sequence or in parallel.  
 Innovation ecosystem: the wider economic, regulatory and political 
environment that may enable or constrain the ability of actors to deliver a 
new product or process, including cultures and identities of collectives and 
individuals.  
The overall framework is designed to support decision making at various levels, 
including companies developing business plans for a specific therapy; groups of 
firms involved in strategy development towards constructing a value chain; policy 
makers considering the impact of a regulatory initiative for a new technology; and 
patient interest groups involved in decision-making on new therapies (Mittra and 
Tait, 2012; Mastroeni et al., 2012; Mittra et al, 2015). The approach can be used by 
actors in any category to consider the impact of their actions on others operating at 
the appropriate level of analysis, and/or to think through how actions in any realm 
may affect their interests and planned actions. It also allows planning for the 
integration of business models along the value chain, as well as taking account of 
how environmental factors can act as enablers or constraints on innovation (Tait et 
al, 2015).  
Life science innovation system stakeholders developing potentially disruptive 
innovations must begin forecasting business models at very early stages of product 
development, often ten to fifteen years ahead of market launch. Scenario analysis is a 
useful tool for planning at this early stage, often based conceptually on qualitative 
data but sometimes data can be used to develop quantitative models. Data for our 
cases come from published and unpublished literature, workshops, and interviews 
with scientists, regulators, companies and public interest groups such as patient 
groups. 
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Figure 1. STRATIS approach 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: adapted from Mastroeni et al, 2012)  
 
The STRATIS approach has been used so far to study, for example, the development 
of clinical grade pluripotent stem cells, a bio-artifical liver device, the production of 
red blood cells (detailed in Mittra et al, 2015), and stratified medical products 
(detailed in Mittra and Tait, 2012). For new regenerative medicine (RM) therapies 
there is as yet no routinized business model, or any straightforward way to tie new 
business approaches to existing business strategy and tactics. Since a good business 
model design is central to sustainable competitive advantage, it is important to build 
scenarios that produce insights on possible ways to capture value. Projected business 
models will be experimental, leading to failures and new versions before robust 
models begin to emerge. 
Business models will also depend on successful negotiation of relations with other 
businesses in other parts of the value-chain as the value chain takes shape (Nature, 
2002). Mason and Manzotti (2009) have argued that there are serious challenges for 
companies wishing to develop RM therapies, which are disruptive of existing 
business models and value chains. New product and process approaches will be 
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needed together with a service infrastructure to support implementation of the 
therapy – that is, not only new business models but new value chains will be created 
(Mastroeni et al, 2012). Such value chains, in turn, will depend on the new 
innovative specialist RM companies finding ways to collaborate with existing big 
pharma and health care providers. 
The innovation ecosystem, the environment within which the value chain is 
embedded, includes complex regulatory, marketing and public/patient interactions. 
An example of a problematic element of an innovation ecosystem for RM products is 
the regulatory system, which is based on that for pharmaceuticals. This regulatory 
system evolved within an innovation ecosystem that increasingly honed clinical 
trials for mass drug use and creates problems for highly stratified and rare disease 
therapies.  But, at the moment, the RM regulatory system has tended to use the 
unsuited drug regulation as its model for all new therapies. Mittra et al (2015) give a 
more detailed explanation of the problematic regulatory system for RM products. 
In the cases studied so far, we have used this three level approach, together with 
scenarios analysis (Van der Heijden, 1996) to build and test conclusions about 
potential future RM value systems.  
Using a software tool (Banxia Decision Explorer) strategic maps were developed. 
Figure 2 gives an example of a summary map, showing critical points in the 
pathway at which scale up and manufacturing would need to be finalised. Similar 
maps can be developed for other types of decision around life science innovation. 
Research and evaluation has also taken place of the extensive public engagement 
elements of product development in these cases. For example, King (2013) undertook 
detailed research on the public engagement programme of red blood cell product 
development, showing both the communication and interactive skills developed by 
scientists and also the ways in which they used the knowledge they gained.  
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Fig 2 Value chain critical points for production of cultured red blood cells 
 
 
 
 
 
 
Source: (Figure 1 From Mittra et al., 2015, New Biotechnology  
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the multiple disciplines that generate knowledge in the life sciences. The rise of 
biology has radically changed the nature of knowledge production in the life 
sciences, but so has the rise in the number of social actors involved. The paper went 
on to show that multiple industrial activity is involved in translating science into 
new products and processes, well beyond the large pharmaceutical and agro-
chemical companies that dominated in the past. Such changes have increased the 
complexity of social interactions between different types of actors. We make the case 
for a systems approach that requires sectoral specificity, holistic analysis of 
interaction between three broad groups of actors: innovators; policy-makers and 
regulators; and publics, bringing co-evolutionary results as knowledge and 
innovation are generated. We go on to argue that new tools are needed and we 
describe one of the tools  used in analysing and re-conceptualising  innovation in the 
new life sciences.  We developed a framework and tools which allows application of 
theoretical perspectives (sectoral specificity, co-evolutionary and systemic 
interaction analysis) to specific cases of business model development of new life 
science products. We worked with stakeholders at three levels from ecosystem to 
value chain and in innovative life science business model developments. Specifically 
with RM products, negotiation of product development involves constant inter-
organisational adaptation as new RM companies find ways to collaborate with 
existing big pharma, health providers and regulators. 
Various insights have emerged from our analysis thatbuild on our theoretical 
underpinnings (section 3).  
1 We demonstrate a new approach to social and natural science 
interdisciplinary collaboration to foresight product development 
pathways. The bringing together of natural and social science knowledge 
is essential if sense is to be made of new business models and value chains 
in development for new RM therapies; 
2 We have illustrated Teece’s argument that a business model is conceptual 
rather than financial. Not only that but since the business models for new 
life science therapies do not yet exist, the STRATIS approach is a means to 
experiment with, and visualise, potential business models and potential 
designs for new products; 
3 We have shown the importance of open innovation approaches if a 
complete value chain is to be shaped. We show (as does Cooke, 2005) the 
importance of the inter-organisational knowledge value chain (containing 
exploration knowledge, examination knowledge and exploitation 
knowledge) and the absorptive capacity requirements for success of such 
open innovation systems; 
4 The STRATIS methodology has brought together a range of aspects of 
value chain analysis for the development of RM therapies, including: 
market identification, complex manufacturing processes and their scale 
and location in the value chain, distribution processes for vulnerable 
living materials, partner selection and collaborative/networking 
approaches, intellectual property and access to cell lines, managing clinical 
trials and other regulatory approval processes, controlling costs and 
identifying alternative sources of value; 
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5 Our triadic approach to the life sciences emphasises the importance of 
integrating regulatory and public stakeholders to avoid antagonistic 
approaches to future technology especially at early developmental stages 
when hype and promise can be fed by the huge uncertainties over what 
might be possible in the middle and distant future. The hype and promise 
associated with new life science technologies can, we found, be attenuated 
through analyses like that of STRATIS integrating business models and 
value chains with enabling and constraining factors in the innovation 
ecosystem. 
We propose that these insights will be of practical, methodological and theoretical 
benefit to analyses of complex innovation systems in life sciences and other new 
technologies. The next step is to use the tools in a diverse group of sectors, to learn 
and to adapt them.  
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